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ABSTRACT: The standard of care in oncology has been genomic profiling of tumor tissue biopsies for the treatment and management of
disease, which can prove to be quite challenging in terms of cost, invasiveness of procedure, and potential risk for the patient. As the number
of available drugs in oncology continues to increase, so too does the demand for technologies and testing applications that can identify
genomic alterations targetable by these new therapies. Liquid biopsies that use a blood draw from the diseased patient may offset the many
disadvantages of the invasive procedure. However, as with any new technology or finding in the clinical field, the clinical utility of an analytical
test such as that of the liquid biopsy has to be established. Here, we review the clinical testing space for liquid biopsy offerings and elucidate
the technical and regulatory considerations to develop such an assay, using our recently validated PlasmaMonitorTM test.
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Introduction

non-invasive surrogates of tumor monitoring,2 with plasma
being preferred across all cancer types.3 CSF is preferred for
tracking central nervous system (CNS) tumors4; saliva for head
and neck cancers5; urine for renal cell carcinoma, bladder, and
prostate cancer2; and stool being used for colorectal and pancreatic cancer.6 The main analytes being evaluated in liquid biopsies
are extracellular vesicles (such as exosomes), circulating tumor
cells (CTCs), and/or residual fragmented DNA3 (Figure 1B).
Exosomes are small round vesicles of endosomal origin,
approximately 50-100 nm in diameter, carrying DNA, RNA,
miRNAs, and proteins released by multiple cell types (including tumor cells) into the extracellular environment.7 As genetic
alterations promote the interphase of cancer cells, the cancer
cells shed from the tumor as CTCs. As cells including CTCs
undergo apoptosis, necrosis, and perhaps secretion,8–10 they
shed fragmented DNA into the circulation. DNA released
irrespective of cell of origin is called cell-free DNA (cfDNA),
and when released specifically by cancer cells, it is referred to as
circulating tumor DNA (ctDNA). Due to concerns of sensitivity and specificity, false negatives in particular, evaluation of
CTCs is therefore not yet fully accepted into clinical practice
for guiding treatment decisions.
cfDNA is a mixture of normal DNA, wild-type DNA from
tumor, as well as mutated DNA from tumor, requiring highsensitivity technologies for detection, particularly since circulating nucleic acids have variable circulating half-lives ranging
from 15 minutes to several hours,11,12 with concentrations of
0-1000 ng/mL of blood in cancer patients and 0-100 ng/mL of
blood in healthy individuals.13,14 Analyzing cfDNA might not

Over the last two decades, cancer diagnostics in the era of precision or personalized medicine has made tremendous headway
with the recent advances in science and technology making it
possible for early detection as well as non-invasive or minimally invasive monitoring, using liquid biopsies. Early detection and molecular characterization of tumors is crucial to a
positive prognostic outcome by guiding therapeutic decisions.
The current standard of care in genotyping solid tumor tissue
for cancer patients to identify somatic gene variants for therapeutic action primarily begins with an invasive surgical biopsy
procedure, limiting the longitudinal follow-up. In contrast, liquid biopsies being minimally invasive allow for evaluation of
the patient at multiple time points during and post-therapy to
assess treatment response as well as for the detection of recurrence, resistance, and minimal residual disease, in theory enabling timely interventions as deemed necessary for effective
management of disease. They also offset the burden of a surgical biopsy and are extremely valuable in cases where a patient is
diagnosed with an inoperable/inaccessible tumor or primary
biopsy of tissue is not possible due to high risk of bleeding or
nerve injury.1
Depending on the cancer type and stage, a number of specimens such as blood (plasma, serum), urine, saliva, pleural effusions, amniotic fluid, nasal secretions, bronchoalveolar lavages,
lymphatic and peritoneal fluids, bone marrow aspirates, cerebrospinal fluid (CSF), prostatic fluid, peritoneal lavage, sputum, gastric juice, breast milk, ascites and biliary, and even stool samples
(Figure 1A) have been evaluated for their potential to serve as
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and diverse landscape of the tumor18; however, the ability of
liquid biopsy tests to predict response to therapy is still the
subject of active investigation in clinical and preclinical
research. When tumors progress and metastasize, tumor sites
may become inoperable. Obtaining a tissue sample that provides a landscape view of the tumor can become highly unlikely
without the use of a liquid biopsy-based assay. Glioblastomas
and spinal cancers can progress quickly, and obtaining a small
tissue sample via a surgical biopsy may not provide a quick
enough turnaround time at a chance to treat the cancer. Even a
moderate amount of hemorrhage that occurs in the biopsy tract
could be potentially threatening to the patient’s neurological
function or even life.19 By implementing liquid biopsy technologies, a simple blood draw can provide real-time genetic
and molecular information about the tumor without the invasive surgical procedure which provides tremendous benefit to
inoperable cancers such as brain and spinal cancers.20

The Current Landscape of Liquid Biopsy Testing

Figure 1. (A) Specimen types and (B) analytes for liquid biopsy.

provide information of the entire landscape of the tumor, especially keeping in mind tumor heterogeneity; however, if appropriate technologies are used, it does enable earlier detection
with prognostic potential to a certain extent.15,16 Studies have
demonstrated that serum has a 3-24 fold increase in cfDNA
compared with plasma, as a result of hemolysis during clotting
or from leukocyte contamination results, with the amount of
contamination increasing with the number of days between
blood withdrawal and serum separation.14,17 Increased cfDNA
in serum is associated with a higher false positive rate, making
plasma the preferred specimen for evaluation of cfDNA.
Evaluating the clinical utility of non-invasive techniques to
detect molecular alterations in CTCs and cfDNA has been a
topic of interest in precision oncology as it provides the potential to safely and cost-effectively monitor the tumor profile at
multiple time points throughout the patient’s clinical course.
This concept of longitudinal testing is made possible through
the economics and practicality of easily accessible specimens
such as blood, saliva, and urine. Furthermore, variable but positive evidence continues to emerge that demonstrates the potential benefit (and limitations) of capturing multiple observations
of a tumor’s genomic profile over time.18 High-frequency monitoring may also prove critical to a physician’s ability to tailor or
change a therapeutic course based on the molecular evolution

With personalized medicine increasingly expanding into the
clinic, more therapeutics are actively being developed and used
in patients based on the molecular profiles of their different
cancer types which is why discovery and classification of these
biomarkers is of utmost importance. Molecular evaluation of
cfDNA in cancer patients has emerged as an attractive option
offering multiple benefits in patients with diverse tumor types,
with a highly precise evaluation of the tumor genomic alteration landscape, reflective of disease burden.21–23
Clinical assays are developed to address an unmet need of the
patient, are geared to a specific disease area, and use standard or
novel technologies available in a specific lab. Detection of
cfDNA requires highly sensitive techniques due to the small
fraction of tumor-specific DNA mixed with wild-type cfDNA
and some amount of genomic DNA from white blood cells.
Standard methods for the detection of known hotspot mutations
are polymerase chain reaction (PCR) based and include nested
real-time PCR, mutant allele-specific PCR, and digital PCR
which include droplet digital PCR (ddPCR), BEAMing, and
microfluidic digital PCR.12 Targeted deep sequencing methods
such as SafeSeq and CAPP-Seq are highly sensitive methods
that allow for the detection of selected single nucleotide variants
(SNVs), copy number variants (CNVs), and rearrangements
across specific regions.12 Next-generation sequencing (NGS)
technologies are currently being applied to cfDNA analysis,
which enables high-throughput, low-cost sequencing to identify
alterations genome wide, including estimation of tumor mutation burden (TMB) and microsatellite instability (MSI).
Strategies for the evaluation of cfDNA depend on the end
goal of identifying resistance, monitoring for minimal residual
disease or prima facie looking for recurrence, to be able to
implement appropriate treatment regimens or companion
diagnostics as available. Toward that end, there are several tests
currently available for clinical testing, ranging from hotspots in
a single gene, full gene coverage, panels for specific cancers, or
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Table 1. Liquid biopsy assays currently available for clinical use.
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a combination of all the above (Table 1). The decidedly selective approach, often designed for the purpose of assessing
highly recurrent loci for mutations that directly inform treatment decisions through on-label use of Food and Drug
Administration (FDA)-approved drugs or recommendations
based on clinical practice guidelines, involves evaluation of hotspots or single genes. An example being the Cobas® EGFR
Mutation Test v2 which is FDA approved for use in non-small
cell lung cancer (NSCLC) patients. Focusing on evaluation of
42 mutations in exons 18, 19, 20, and 21 in the EGFR gene,
this test aims to help patients with NSCLC that may not be
suitable to undergo an invasive procedure and a genetic test
focusing on the EGFR gene alone may be beneficial for therapy. An expanded approach for patients with an unknown primary tumor site would involve using a panel of genes such as
the Guardant360 assay,24 which includes 73 genes in which all
exons are completely sequenced to exploit the detection of
known somatic variants. Similar to other tests currently available for clinical use that span the spectrum of hotspots, through
single gene and/or encompass multiple genes (Table 1), this
panel is used across different cancer types and specimens (blood
and/or formalin fixed paraffin embedded-FFPE tissue) and
can be used to identify multiple therapeutic targets.
Depending on the approach taken, there are associated
advantages, limitations, and challenges. In terms of clinical utility, single gene evaluation offers disease-specific coverage, a
shorter turnaround time, is cost effective, and most importantly
from a patient perspective, in the case of NSCLC as exemplified,
is that the variants evaluated if detected are associated with targeted therapies. However, there are also limitations with single
gene assays, in terms of the potential to miss variants in other
genes not being evaluated. The FDA-approved Cobas® EGFR
Mutation Test v2 panel as outlined above targets specific EGFR
mutations in NSCLC patients exclusively, missing other mutations in genes such as ALK, BRAF, KRAS, MEK, and MET
which also have potential to provide therapeutic yield.25 Another
concern with such an approach is the observation that the frequency of EGFR gene mutations in NSCLC patients when
undergoing chemotherapy decreases26 and therefore although
approved by the FDA, this assay may not represent a suitable test
for monitoring NSCLC patients receiving chemotherapy.11,26
When designing a single gene panel, identifying gene mutations
with associated therapies is crucial but taking into consideration
other factors that will impact a false-negative result is equally
critical. While single gene panels offer a comprehensive view of
the mutations that exist within that gene, significant data and
information on the tumor can be lost without looking at possible
mutations that may exist elsewhere and may be important for
the treatment of the tumor.
Larger panels may not always be the best option in a clinical
setting, as the cost increases and sequencing depth decreases per
gene, the overall benefit to the patient can be uncertain but the
greater potential to assess prognosis, detect recurrence, and get
an insight into difficult-to-diagnose tumors remains present.11
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With a larger scope of genes to look at comes many variables and
with that a multitude of challenges. In a recent cross-assay comparison, both the Guardant360 panel (Guardant Health Inc)
and the PlasmaSELECT-R64 panel (Personal Genome
Diagnostics) were run on identical metastatic prostate cancer
patient samples to determine the reliability and potential utility
of these assays.27 To determine concordance across both tests,
only genetic alterations in genes supposedly covered by both
platforms (42 genes) were considered. Patients with one or more
alterations demonstrated by at least one platform (31 of 40),
whose all cfDNA alterations were covered by only one of the
tests, were excluded (6 of 40). Only 3 (7.5%) of the 40 patients
had complete congruence with one or more alterations. There
are a number of reasons for the lower concordance including
small sample size, variation in genes evaluated (regions of coverage, depth of coverage, etc), timing of different samples collected,
but most importantly differences in limit of detection (LOD).
This study suggests that the lack of concordance in genetic profiling across platforms and technologies could jeopardize the
clinical benefit of personalized medicine. It also emphasizes that
standardization of technologies and procedures across laboratories is needed to ensure consistency of results.

Development and Validation of the JAX
PlasmaMonitor™

To provide comprehensive monitoring of cancers, the Jackson
Laboratory ( JAX) designed a non-invasive liquid biopsy assay to
complement the current oncology test menu in the clinical laboratory. The JAX PlasmaMonitorTM was developed to cater to our
patient pool which primarily consists of stage IV metastatic cancers and was therefore developed as a pan cancer panel (Figure 2).
Being able to use the PlasmaMonitorTM to track the progression
of cancer, monitor any arising clones that may develop resistance
to treatment therapy, as well as recognizing new possible therapies as the tumor evolves is an undoubtable benefit. While maintaining the highest of standards, the assay was to include the most
clinically relevant genes across a wide scope of cancer types
(Figure 2A-C) that could be provided to the clinician in a reasonable amount of time, in a cost effective way, and was therefore
designed to be a 14 gene, 84 variant hotspot pan cancer panel
(Figure 2A).
To determine the coverage of the panel per cancer type, as
an estimate of clinical utility, as the panel was designed, we
used all the variants in catalog of somatic mutations in cancer
(COSMIC) for each individual cancer type (such as breast
cancer) to filter that list to contain only the variants present in
the PlasmaMonitorTM for that tumor type. Data for the number of variants present in the panel identified for a specific gene
in that tumor type and the number of samples mutated with
those variants on our panel in a specific gene for that tumor
type were narrowed down (Figure 2C). The goal was to provide
an assay that could offset the disadvantages of a single gene and
multi-gene panel while maintaining the benefits and integrity
of what liquid biopsy panels are able to offer.

Panel design
To identify the most appropriate gene content for the panel, we
scanned the literature to identify gene/variants with therapeutic, prognostic, and/or diagnostic impact; evaluated the positive
yield rate from our solid tumor NGS panels; and collated the
information to design a panel primarily based on the actionability of variants (Figure 2D). Actionability being defined as
evidence of response or resistance to FDA approved therapies
and/or investigational therapies, availability clinical trials
recruiting for a specific gene/variant, and evidence of prognostic significance (Figure 2E). While the PlasmaMonitorTM is a
smaller panel compared with some currently offered on the
market (Table 1), it includes clinically relevant hotspot mutations in genes across multiple cancer types (Figure 2A-C).

Technical considerations
As elucidated so far, while genomic profiling for tumor mutations has been successfully demonstrated from cfDNA, the low
amount of cfDNA in the blood, which can be less than 1%
allelic frequency, presents significant challenges for reliable
variant detection. As our NGS panel was developed, technical
and analytical factors were evaluated to develop a test with
high sensitivity and specificity, keeping in mind the LOD for
low (<1%) variant allelic frequency (VAF).
Optimization of pre-analytical parameters such as plasma
separation and selection of an isolation method that ensures
extraction of a sufficient amount of high-quality DNA is critical. It has been shown that these pre-analytical factors of blood
sampling and processing can strongly affect DNA yield24
as well as downstream analysis. The development of
PlasmaMonitorTM included evaluation of plasma separation
and cfDNA extraction methods to maximize yield of quality
DNA in a scalable, cost-effective manner. Introduction of an
additional centrifugation step at 16 000 g for 10 minutes, post
separation of plasma from whole blood resulted in decreased
debris. We evaluated four commercial cfDNA extraction kits
across 35 samples; QIAamp circulating nucleic acid kit
(Qiagen), NucleoSpin Plasma XS (Macherey-Nagel), ZR
Serum DNA kit (ZYMO Research), and the NEXTPrep-Mag
cfDNA isolation kit (Bioo Scientific) (Figure 3A). Based on
the yield, scalability, turnaround time for processing, and cost
effectiveness, we opted for the NEXTPrep-Mag cfDNA isolation kit.
Current cfDNA extraction methods yield modest quantities
of nucleic acid content, emphasizing the importance of sensitive
and accurate quantification and qualification of cfDNA in the
molecular sequencing process. Although we realize that a bioanalyzer analysis to assess fragment size and quality is widely
accepted to be the norm, we evaluated and validated the use of a
modified Human Genomic DNA (HGD) QC Assay for quantification and qualification of the extracted cfDNA to enable effective downstream processing, taking into consideration DNA
integrity index (DIN). To be able to establish this method as a
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Figure 2. PlasmaMonitor™ panel design, content, and criteria for inclusion. (A) Lists the 14 genes on the panel with specific hotspots across each gene;
(B) outlines the coverage of the different variants across various cancer types; (C) represents the percentage coverage of panel across certain tumor
types, using the number of samples mutated with those variants on our panel in a specific gene for that tumor type; (D) schematic for the logic that went
into picking gene content; and (E) lists the criteria considered to determine actionability of a gene/variant.
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Figure 3. PlasmaMonitor™ pre-analytical and technical considerations. (A) Comparison of four commercial cfDNA extraction kits for yield; (B)
quantification and qualification of the extracted cfDNA using a custom Human Genomic DNA QC Assay; (C) comparison data demonstrating that using
our custom quality approach provides more robust quantification data in comparison with the standard Qubit assay; (D) pre-analytical validation steps
including sensitivity and limit of detection (LOD), inter-assay reproducibility, intra-assay reproducibility, and specificity and accuracy; (E) post-sequencing
validation steps including sensitivity and LOD, inter-assay reproducibility, intra-assay reproducibility, and specificity and accuracy.

QC step in our process, we performed a comparative evaluation
of a Qubit Fluorometric 2.0 Assay vs a HGD QC Assay (Figure
3B). Cell-free DIN is measured as the ratio of long-to-short
DNA fragments.28 cfDNA from apoptotic cells is uniformly
truncated into 180-200 bp fragments, whereas cfDNA from
necrotic tumor cells varies in length, leading to elevation of larger
fragment DNA.29 Our results clearly demonstrated that using
our custom HGD quality control approach provides more robust
quantification of cfDNA in comparison with the Qubit assay.
The method is also capable of generating a quality metric absent
from the Qubit approach to assess for the presence of high
molecular weight DNA contamination. When used to prepare a
subset of samples for NGS, these quantity and quality measures
produced libraries that passed clinical quality sequencing metrics
(Figure 3C). By running qPCR for both 129 and 305 bp, we are
more accurately able to discern quality of the sample through
looking at the portion of sample that is greater than 129 and 305
bps. As cfDNA exhibits a narrow size distribution around 160180 bp, 129-bp qPCR results accurately detect the total quantity
of cfDNA and high molecular weight gDNA. 305-bp qPCR

results indicate only the presence of high molecular weight cellular gDNA contamination.
Validation for the PlasmaMonitorTM for clinical use
included sequencing of 21 molecularly uncharacterized tumor
samples, and 14 known controls under established metrics and
was completed in 5 phases: (1) sample processing for validation
parameter determination; (2) LOD, sensitivity, specificity, and
accuracy; (3) inter-assay concordance; (4) intra-assay concordance; and (5) clinical validity in terms of interpretation and
reporting of variants identified, per recommended guidelines30,31 (Figure 3D and E). The final clinical protocol was
developed using an input of 10 ng of cfDNA quantified and
qualified by a custom qPCR assay to establish DIN values,
where ⩽0.8 was considered optimal (Table 2). Using samples
containing variants with known allele frequencies and ddPCRbased confirmation of novel variants identified by our assay, we
established the assay’s LOD.
We used the SeraSeq ctDNA reference materials which contain a list of 11 hotspot cancer mutations at known allele frequency (1.2%, 0.5%, and 0.1%) in the following genes: AKT1,
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Table 2. Established pre-analytical and sequencing quality control cutoffs for PlasmaMonitorTM.
Technical parameter

Established metric

Extraction (ng)

⩾10

DNA integrity score

⩽0.8

Final library concentration (ng/µL)

⩾0.5

Mean target coverage

⩾20 000

Table 3. PlasmaMonitor™ analytical performance characteristics and
results.
Performance
characteristics

Results

Accuracy

98%

Sensitivity

96%

Specificity

100%

Precision (repeatability
and reproducibility)

100%

LOD

0.9% SNVs and indels

Reportable range

Variants detected/not detected
above the LOD within the region
of interest. No regions of low
coverage observed

BRAF, EGFR, KRAS, PIK3CA, and TP53. In addition, we used
three clinical samples with ddPCR-validated hotspot variants at
0.6%, 1%, and 5% allele frequency. Using these samples and the
corresponding SeraSeq circulating tumor wild-type control, we
designed a titration experiment to obtain samples with allele frequencies of 0.2%, 0.3%, 0.4%, 0.6%, 0.7%, 0.8%, 0.9%, and 1%.
At each allele frequency from 0.1% to 1.2%, we then evaluated
the assay’s ability to correctly identify known variants (sensitivity). At allele frequency of ⩾0.9%, we achieved a sensitivity of
~96% and we therefore deduced 0.9% as our assay’s LOD. At
this LOD, sensitivity, specificity, and accuracy were found to be
96.6%, 100%, and 98%, respectively (Table 3). As the validation
results indicate, the PlasmaMonitorTM is a well designed genetic
test that is able to provide a comprehensive actionable report to
the patient (Supplemental Figure 1).

Current Guidelines (Recommendations) for ctDNA
Testing

A joint review assessing ctDNA testing in oncology was
recently released by the American Society of Clinical Oncology
(ASCO) and the College of American Pathologists (CAP).32
This review surveyed the current status of ctDNA analysis in
the field and provides a framework for the future development
of ctDNA tests. The guidelines outline four areas of significance, namely, pre-analytical challenges, analytical validity,
interpretation and reporting of variants, and the clinical

validity and clinical utility (Table 4) to be specifically considered during the development of ctDNA assays.32
Receipt and processing of clinical samples has to follow the
same established process (stringency and quality control) for
each sample from beginning (accessioning) to end (sending the
report out to the physician). Pre-analytical considerations33
include optimal blood sampling, handling protocols, and longterm plasma and cfDNA storage which need to be considered
in parallel with test validation criteria32 (Figure 3D and E).
Specimen handling from collection through shipping, transportation, and storage needs to be performed with the utmost
care and adherence to regulations including chain of custody,
while addressing sample stability since these aspects are critical
and impact downstream processing.
Shipping and storage conditions of the plasma samples can
cause varying concern as stability can decrease in a few days.
To offset these variables, clinical testing laboratories including
JAX provide a requisition form that includes acceptable conditions of samples to ensure that the collecting site is aware of
the requirements prior to sample collection. It has been shown
that improper shipping and storage conditions may lead to
damage of DNA nucleases resulting in genomic DNA contamination. An additional aspect of specimen collection is the
blood draw site, as no data are currently available comparing
blood acquisition from other sites compared with peripheral
veins, and phlebotomists should follow the tube manufacturer’s instructions for use.32
Plasma is stable when stored at −80°C for long-term storage. While using plasma, attention should be paid to the type
of tubes used for blood collection. Stability of cfDNA can be
increased using EDTA since it inhibits nuclease (DNAse I)
activity; heparin, however, has been shown to impact downstream processing of plasma including yield of cfDNA
obtained. Condition of specimen is also equally important, particularly in terms of hemolysis, which can spuriously increase
DNA yields. However, blood storage tubes incorporating
EDTA, have a bigger incidence rate of genomic DNA (gDNA)
contamination if blood is stored in them for more than 7 days.
gDNA increased ~2-fold on day 14 in blood collection tubes
(BCT) tubes (Streck) as opposed to a 456-fold increase in
K3EDTA tubes,34 making them the preferred tubes for specimen collection for liquid biopsies. Upon receipt of the blood
sample at JAX, to ensure proper sample processing and downstream analysis of the PlasmaMonitorTM, plasma is immediately isolated and stored in the −80°C freezer to maintain
stability and avoid degradation and contamination of DNA.
Analytical validity is essential and needs to be clearly established for all clinical grade assays. Currently, the ASCO/CAP
consensus for cfDNA assays concludes that there is a discordance between solid tumor sequencing and liquid biopsy testing
and therefore suggests that solid tumor evaluation be followed
by a liquid biopsy assay for concordance and recommend the
confirmation of variants identified in liquid biopsy assays by
orthogonal methods.32 A critical aspect of the difference
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Table 4. Summary of ASCO/CAP (Merker, Oxnard and Compton, 2018) considerations for liquid biopsy assays in the clinic.
Considerations

Paper consensus examples

Pre-analytical

• Plasma is suggested to be the optimal specimen type for analysis of circulating tumor DNA (ctDNA).
• Specimen collection, handling variables, storage condition and time, and patient-related biological factors need to be
studied further to assess the affect these variables play in ctDNA analysis.
• Sample processing should be started immediately upon receipt, no later than 48 hours post collection, if stored in cell
stabilization tubes.

Analytical validity

• There is discordance between the results obtained from solid tumor profiling and liquid biopsy, and supports
confirmation of variants obtained from evaluation of solid tumors.
• Defining assay limit of detection (LOD) is of utmost importance:
   LOD may vary across the differing genes on a panel and the target specimen type therefore needs to be taken into
consideration when defining the LOD.
    More cross panel testing is needed to set stricter LOD standards for ctDNA assays to function as reliable standalone assays.

Interpretation and
reporting variants

• Incorporation of any available clinical information as well as information from tumor analysis, particularly with the
identification of an actionable somatic variant in a ctDNA assay, is important to provide appropriate therapeutic options.
• The fraction of ctDNA present in total cell-free DNA in plasma varies significantly between different patients:
    Variant allele frequency of potentially actionable variants called from ctDNA assays need further study.
• Caution is needed when reporting whether a somatic variant is or is not identified by a ctDNA assay:
    Should be conveyed with understanding of possible discordance if compared with a solid tissue test.

Clinical validity

• There is only emerging evidence of clinical validity in the application of liquid biospy assays.
• Concerns still remain regarding clinical validity of liquid biopsies including quantifying tumor origin and minimum
residual disease.

Clinical utility

• Currently there is no evidence of clinical utility with this application as a stand alone test.
• Acknowledges that there is evidence that may support initiation of a targeted therapy when a ctDNA assay identifies a
relevant genomic marker that is concordant with results from tumor tissue.

between solid tumor and plasma-based evaluation is the LOD
and VAF. Defining LOD for an assay is of utmost importance,
for ctDNA assays in particular, the LOD will be lower than
those of solid tumor genotyping assays due the small amounts
of DNA being shed from the tumor.
Similar to FoundationOne® Liquid panel (Table 1), which
can act as a stand-alone panel or accompany the FoundationOne
CDx™ FDA-approved solid tumor panel, the PlasmaMonitorTM
is established to be used for the evaluation of both solid tumor as
well as plasma samples. The PlasmaMonitorTM has a LOD of
0.9%, which complements our solid tumor assay and allows for
variant detection as well as confirmation, if needed. We do note
that there are other liquid biopsy tests currently available such as
the Guardant360 which can detect very low-frequency variants
(0.01%), in contrast to the PlasmaMonitorTM. For those variants
identified in our solid tumor evaluation that are not present in
the PlasmaMonitorTM, we have developed and validated a
ddPCR assay. In line with the shortcomings acknowledged by the
ASCO/CAP consensus panel, we approached the concern of the
liquid biopsy test being less reliable when compared with solid
tumor testing, in terms of the high false-positive rate, by orthogonally confirming mutations detected by PlasmaMonitorTM
using ddPCR, prior to reporting detected gene variants. We have
also restricted analysis to only three nucleotide positions within
a given hotspot for effective variant detection. False-negative
results still remain a challenge and continued optimization
efforts are ongoing to ensure that the PlasmaMonitorTM can
accurately act as a confirmation assay to deliver the most accurate
information to the patients we serve. With regard to performance of monitoring setting across a subset of clinical samples in

different time points, we predict and expect that samples regardless of time points pass all set QC thresholds for the assay.
The ASCO/CAP review also raises a concern regarding the
issue of discerning between analytical and clinical validity of
liquid biopsies. Clinical validity including quantifying tumor
origin and minimum residual disease leads the article to conclude that there is only emerging evidence of clinical validity in
this application.32 For the PlasmaMonitorTM, our intent would
be to monitor the detection of variants being directly targeted
for therapy or the emergence of well-established resistance
mutations in the patient. Our validation included appropriate
dilution experiments to stratify detection along a variety of
ranges and the operational LOD cut-off was chosen above
theoretical LOD to minimize false-positive results (Figure
3D). We agree that there are serious limitations, both technical
and interpretive with the analytical and clinical validity. We
therefore make zero claims or recommendations regarding
such relationships, rather, only focusing on them as limitations
of the assay.
In addition to clinical validity, clinical utility is yet to be
demonstrated for the evaluation of cfDNA to monitor disease.
To combat the absence of clinical utility on its own, physicians
receiving results from our PlasmaMonitorTM have access to a
multidisciplinary genomic tumor board to discuss the utility of
the reported results (Supplemental Figure 1) on a case-by-case
basis thus providing a method of clinical utility for our patients.
For the reasons above, we believe we have employed the assay
as responsibly as can be done with current research/knowledge/
evidence while addressing the needs and demands of a diverse
patient and physician population.
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Challenges and Limitations of Liquid Biopsy Assays

Although liquid biopsy has the potential to be an effective
assay in the detection of clinically relevant variants, monitoring
the progression of cancer via evaluating exosomes, CTCs or
cfDNA, can be challenging due to multiple factors including
but not limited to tumor stage, tumor type, tumor heterogeneity, and tissue of origin, necessitating the need for high sensitivity and specificity and increased robustness of current
technologies. Because cfDNA is a mix of normal DNA as well
as non-mutated tumor DNA in addition to tumor DNA, separating out enough ctDNA can prove to be a challenge depending on tumor type and stage.
Allelic frequencies and tumor heterogeneity contribute to
the false-negative rate. In early-stage tumors especially,
genomic alterations have been known to be present at very low
variant allele frequency (VAF) which increases the sensitivity
and the specificity35 needed for the assay to detect these variants.36 ctDNA used for genomic variant genotyping represents
an extremely small fraction of the tumor, in some cases only
less than 0.01%.37 In parallel, CTCs in early-stage tumors
commonly occur at extremely low frequencies, making detection and recovery of the individual cells a burdensome process.
Detection of CTCs requires a greater volume of blood from
the patient or highly sensitive and specific analytic methods
with complex enrichment steps to receive optimal results.12,38,39
CTCs and cfDNA both when targeted, sequenced, and molecularly characterized might only represent a subpopulation of
the tumor in the intra-tumor heterogeneity landscape.12
Aiming to capturing the full heterogeneity of the tumor with
ctDNA presents the possibility of the presence of DNA from
normal cells. This leaves room for misinterpretation of the
tumor because of the background presence of leukocytes and
the overlap they may have with cancer cells for the genes of
interest.40 Specimen quality, short half-life of CTCs, and circulating nucleic acids as well impact the final results. The
PlasmaMonitorTM was developed to follow mutations detected
in paired solid tumor/plasma samples at low VAF and LOD,
with the aim to reduce false-negative results; however, stage of
cancer and tumor heterogeneity could yet contribute to the
false-negative calls of the assay.

Discussion and Conclusions

In conclusion, liquid biopsy has the advantage of being a
minimally invasive or non-invasive quick method for the
detection and analysis of circulating biomarkers, enabling us
to evaluate a patient at multiple time points during disease
management. However, given the absence of clinical utility
and the need for highly sensitive robust technologies to better address the false-positive and false-negative rates, the
liquid biopsy assays are still in their infancy, leaving the tissue biopsy as the superior method of targetable mutation
identification across a majority of different tumor types.
The JAX PlasmaMonitorTM provides detection of 84

hotspot SNVs and indels across 14 clinically actionable
genes to provide relevant clinical information to both the
treating physician and the patient, post-solid tumor testing,
as a way to follow known mutations and monitor disease.
Given the promise of this area of precision medicine, there
is clearly a focused effort in driving the current technologies
to address this unmet need of the patient, with the goal to
make liquid biopsy a surrogate to traditional methods of
tumor profiling to play a significant role in the early detection, prognostication, and therapy guidance.
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